SCHEMBL8302208

SCHEMBL8302208

Cc1nc2cc(C(=O)N3CCN(C4CCN(C)CC4)CC3)ccc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 7/20 0.57
L3MBTL1 Q9Y468 6/20 0.57
TLR9 Q9NR96 2/20 0.49
TLR7 Q9NYK1 2/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
FGFR1 P11362 2/20 0.47
FGFR2 P21802 2/20 0.47
FGFR3 P22607 2/20 0.47
TLR8 Q9NR97 1/20 0.45
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
BRD4 O60885 1/20 0.44
ACACB O00763 1/20 0.43
ACACA Q13085 1/20 0.43
TP53BP1 Q12888 2/20 0.43
MBTD1 Q05BQ5 1/20 0.43
L3MBTL4 Q8NA19 1/20 0.43
KDR P35968 1/20 0.43
SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12252341 0.89 CNR2 (0.47) L3MBTL3L3MBTL1MEN1KMT2AFGFR1
SCHEMBL8262960 0.89 MEN1 (0.60) TLR9TLR7MEN1KMT2AFGFR1
SCHEMBL13290560 0.81 KMT2A (0.47) MEN1KMT2AFGFR1FGFR2FGFR3
SCHEMBL17468532 0.79 HRH4 (0.62) MEN1KMT2AFGFR1FGFR2FGFR3
SCHEMBL13290574 0.79 TLR9 (0.53) TLR9TLR7MEN1KMT2ATLR8
SCHEMBL13290581 0.79 AKR1C3 (0.56) TLR9TLR7MEN1KMT2AFGFR1
SCHEMBL8262965 0.78 ACACB (0.48) TLR9TLR7MEN1KMT2ATLR8
SCHEMBL8264513 0.78 FGFR1 (0.55) KMT2AFGFR1FGFR2FGFR3ALDH1A1
SCHEMBL13290584 0.77 MAPK1 (0.48) L3MBTL1MEN1KMT2AFGFR1FGFR2
SCHEMBL14924454 0.76 L3MBTL3 (0.79) L3MBTL3L3MBTL1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140010892-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2014-01-09 US disclosed
US-20140010892-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2014-01-09 US disclosed
US-20110224203-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2011-09-15 US disclosed
US-20110224203-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2011-09-15 US disclosed
US-7977477-B2 Benzimidazole derivatives and their use as protein kinase inhibitors ASTEX THERAPEUTICS, LIMITED (GB) 2011-07-12 US disclosed
US-7977477-B2 Benzimidazole derivatives and their use as protein kinase inhibitors ASTEX THERAPEUTICS, LIMITED (GB) 2011-07-12 US disclosed
EP-2305250-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS Astex Therapeutics Limited (GB) 2011-04-06 EP disclosed
US-20080312223-A1 Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases ASTEX THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
US-20080312223-A1 Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases ASTEX THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
US-20070135477-A1 Benzimidazole derivatives and their use as protein kinases inhibitors ASTEX THERAPEUCTICS, LIMITED (US) 2007-06-14 US disclosed
US-20070135477-A1 Benzimidazole derivatives and their use as protein kinases inhibitors ASTEX THERAPEUCTICS, LIMITED (US) 2007-06-14 US disclosed
WO-2005002552-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224203-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS CDK1, CCNI, CDK2 L3MBTL3 3228/4885L3MBTL1 3063/4885TLR9 4775/4885
US-20140010892-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS CDK1, CCNI, CDK2 L3MBTL3 3228/4885L3MBTL1 3063/4885TLR9 4775/4885
US-20080312223-A1 Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases CDK1, CDK8, CDK2 L3MBTL3 2199/4885L3MBTL1 2639/4885TLR9 4364/4885
US-20070135477-A1 Benzimidazole derivatives and their use as protein kinases inhibitors CDK1, AURKA, CDK2 L3MBTL3 3866/4885L3MBTL1 2624/4885TLR9 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.